Asparaginase‐associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia
Year: 2012
Type: article
Abstract: Although L-asparaginase (ASP) is associated with several toxicities, its myelosuppressive effect has not been well characterized. On DFCI ALL Consortium Protocol 05-01 for children with newly diagnosed acute lymphoblastic leukemia, the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients, except ASP was given only during Consolidation. Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate. The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents.
Source: Pediatric Blood & Cancer
DOI: 10.1002/pbc.24182
Authors: Reid Merryman, Kristen E. Stevenson, William J. Gostic, Donna Neuberg, Jane O'Brien, Stephen E. Sallan, Lewis B. Silverman
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
OpenAlex ID: W2109139880